Skip to main content
SpringerLink
Log in

Fabry Disease in Females

  • Chapter
  • First Online:
Fabry Disease

Abstract

Anderson-Fabry disease is an X-linked lysosomal storage disorder resulting from deficiency of alpha galactosidase A and accumulation of globotriaosyl ceramide (Gb3) in cells throughout the body. Despite X-linked inheritance, females with Fabry disease may manifest significant multi-system pathology with effects on organ function, physical symptoms, quality of life and survival. Lyonisation within the peripheral blood results in some females exhibiting normal plasma or leucocyte enzyme activities which can lead to difficulties in diagnosis. Evidence of Gb3 storage has been found in urine and plasma and by histological analysis of renal and cardiac biopsies. However the disease causing mechanisms, given the presence of some enzyme activity from the normal alpha galactosidase A gene are not clear. Therapeutic effects of alpha galactosidase A have been demonstrated in the clinical trials, registries and case studies of females with documented improvements in pain, quality of life, left ventricular cardiac mass, and stabilised renal function. The optimum timing for initiation of enzyme replacement therapy nor its role in pregnancy and lactation is unknown. There is a necessity to develop strategies to identify which females are most like to benefit from Fabry specific therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kint JA (1970) Fabry’s disease: alpha-galactosidase deficiency. Science 167:1268–1269

    Article  PubMed  CAS  Google Scholar 

  2. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775

    Article  PubMed  CAS  Google Scholar 

  3. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43:347–352

    Article  PubMed  CAS  Google Scholar 

  4. Whybra C, Kampmann C, Willers I et al (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24:715–724

    Article  PubMed  CAS  Google Scholar 

  5. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M (2003) Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 26:617–627

    Article  PubMed  CAS  Google Scholar 

  6. Whybra C, Miebach E, Mengel E et al (2009) A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 11:441–449

    Article  PubMed  CAS  Google Scholar 

  7. Lyon MF (1961) Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature 190:372–373

    Article  PubMed  CAS  Google Scholar 

  8. Happle R (2006) X-chromosome inactivation: role in skin disease expression. Acta Paediatr Suppl 95:16–23

    Article  PubMed  Google Scholar 

  9. Mills K, Morris P, Lee P et al (2005) Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease. J Inherit Metab Dis 28:35–48

    Article  PubMed  CAS  Google Scholar 

  10. Cable WJ, McCluer RH, Kolodny EH, Ullman MD (1982) Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment. Neurology 32:1139–1145

    Article  PubMed  CAS  Google Scholar 

  11. Gupta S, Ries M, Kotsopoulos S, Schiffmann R (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 84:261–268

    Article  CAS  Google Scholar 

  12. Osunkoya AO, Agte SD, Laszik ZA (2006) 67-year-old woman with chronic proteinuria. Focal segmental and global glomerulosclerosis with light microscopic and ultrastructural features consistent with Fabry disease. Arch Pathol Lab Med 130:e93–e95

    PubMed  Google Scholar 

  13. Chimenti C, Pieroni M, Morgante E et al (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047–1053

    Article  PubMed  CAS  Google Scholar 

  14. Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812–2817

    Article  PubMed  CAS  Google Scholar 

  15. Mehta A, Clarke JT, Giugliani R et al (2009) Natural course of Fabry disease: changing pattern of causes of death in. J Med Genet 8:548–552

    Article  Google Scholar 

  16. Ashton-Prolla P, Ashley GA, Giugliani R, Pires RF, Desnick RJ, Eng CM (1999) Fabry disease: comparison of enzymatic, linkage, and mutation analysis for carrier detection in a family with a novel mutation (30delG). Am J Med Genet 84:420–424

    Article  PubMed  CAS  Google Scholar 

  17. Desnick RJ, Bernstein HS, Astrin KH, Bishop DF (1987) Fabry disease: molecular diagnosis of hemizygotes and heterozygotes. Enzyme 38:54–64

    PubMed  CAS  Google Scholar 

  18. Kleijer WJ, Hussaarts-Odijk LM, Sachs ES, Jahoda MG, Niermeijer MF (1987) Prenatal diagnosis of Fabry’s disease by direct analysis of chorionic villi. Prenat Diagn 7:283–287

    Article  PubMed  CAS  Google Scholar 

  19. Desnick RJ (2007) Prenatal diagnosis of Fabry disease. Prenat Diagn 8:693–694

    Article  Google Scholar 

  20. Bennett RL, Hart KA, O’rourke E et al (2002) Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns 11:121–146

    Article  PubMed  Google Scholar 

  21. Raas-Rothschild A, Lacombe D (2008) Fabry disease prenatal diagnosis. Prenat Diagn 28:268

    Article  PubMed  Google Scholar 

  22. Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 3(333):288–293

    Article  Google Scholar 

  23. Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T (1996) Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet 33:682–688

    Article  PubMed  CAS  Google Scholar 

  24. Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112–128

    Article  PubMed  CAS  Google Scholar 

  25. Giacomini PS, Shannon PT, Clarke JT, Jaigobin C (2004) Fabry’s disease presenting as stroke in a young female. Can J Neurol Sci 31:112–114

    PubMed  Google Scholar 

  26. Whybra C, Wendrich K, Ries M, Gal A, Beck M (2001) Clinical manifestation in female Fabry disease patients. Contrib Nephrol 136:245–250

    Article  PubMed  Google Scholar 

  27. Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G (2002) Clinical features of Fabry’s disease in Australian patients. Intern Med J 32:575–584

    Article  PubMed  CAS  Google Scholar 

  28. Nakayama Y, Tsumura K, Yamashita N, Yoshimaru K (1999) Dynamic left ventricular arterial pressure gradient and sick sinus syndrome with heterozygous Fabry’s disease improved following implantation of a dual chamber pacemaker. Pacing Clin Electrophysiol 22:1114–1115

    Article  PubMed  CAS  Google Scholar 

  29. Cantor WJ, Daly P, Iwanochko M, Clarke JT, Cusimano RJ, Butany J (1998) Cardiac transplantation for Fabry’s disease. Can J Cardiol 14:81–84

    PubMed  CAS  Google Scholar 

  30. Kleinert J, Dehout F, Schwarting A et al (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19:782–787

    Article  PubMed  Google Scholar 

  31. Yuen NW, Lam CW, Chow TC, Chiu MC (1997) A characteristic dissection microscopy appearance of a renal biopsy of a Fabry heterozygote. Nephron 77:354–356

    Article  PubMed  CAS  Google Scholar 

  32. Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236–242

    Article  PubMed  CAS  Google Scholar 

  33. Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry’s disease. Ann Neurol 40:8–17

    Article  PubMed  CAS  Google Scholar 

  34. Grewal RP, McLatchey SK (1992) Cerebrovascular manifestations in a female carrier of Fabry’s disease. Acta Neurol Belg 92:36–40

    PubMed  CAS  Google Scholar 

  35. Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30:943–951

    Article  PubMed  CAS  Google Scholar 

  36. Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34–45

    Article  PubMed  CAS  Google Scholar 

  37. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760

    Article  PubMed  CAS  Google Scholar 

  38. Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28: 1228–1235

    Article  PubMed  Google Scholar 

  39. Eng CM, Banikazemi M, Gordon RE et al (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711–722

    Article  PubMed  CAS  Google Scholar 

  40. Schiffmann R, Kopp JB, Austin HA III et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. J Am Med Assoc 285:2743–2749

    Article  CAS  Google Scholar 

  41. West M, Nicholls K, Mehta A et al (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20:1132–1139

    Article  PubMed  CAS  Google Scholar 

  42. Hughes DA, Elliott PM, Shah J et al (2007) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart 94:153–158

    Article  PubMed  Google Scholar 

  43. Moore DF, Altarescu G, Herscovitch P, Schiffmann R (2002) Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2:4

    Article  PubMed  Google Scholar 

  44. Schiffmann R, Floeter MK, Dambrosia JM et al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703–710

    Article  PubMed  CAS  Google Scholar 

  45. Hoffmann B, Garcia dL, Mehta A, Beck M, Widmer U, Ricci R (2005) Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 42:247–252

    Article  PubMed  CAS  Google Scholar 

  46. Hoffmann B, Reinhardt D, Koletzko B (2004) Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease. Eur J Gastroenterol Hepatol 16:1067–1069

    Article  PubMed  Google Scholar 

  47. Hajioff D, Goodwin S, Quiney R, Zuckerman J, MacDermot KD, Mehta A (2003) Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr Suppl 92:28–30

    Article  PubMed  CAS  Google Scholar 

  48. Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838–844

    Article  PubMed  CAS  Google Scholar 

  49. Banikazemi M, Ullman T, Desnick RJ (2005) Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 85:255–259

    Article  PubMed  CAS  Google Scholar 

  50. Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547–1557

    Article  PubMed  CAS  Google Scholar 

  51. Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86

    PubMed  Google Scholar 

  52. Hajioff D, Hegemannn S, Conti G et al (2006) Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 36:663–667

    Article  PubMed  CAS  Google Scholar 

  53. Hoffmann B, Schwarz M, Mehta A, Keshav S (2007) Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 5:1447–1453

    Article  PubMed  Google Scholar 

  54. Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy–a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23:535–542

    Article  PubMed  Google Scholar 

  55. Wendt S, Whybra C, Kampmann C, Teichmann E, Beck M (2005) Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis 28:787–788

    Article  PubMed  CAS  Google Scholar 

  56. Benichou B, Goyal S, Sung C, Norfleet AM, O’Brien F (2009) A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 96:4–12

    Article  PubMed  CAS  Google Scholar 

  57. Vedder AC, Breunig F, Donker-Koopman WE et al (2008) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94:319–325

    Article  PubMed  CAS  Google Scholar 

  58. Whybra C, Kampmann C, Krummenauer F et al (2004) The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65:299–307

    Article  PubMed  CAS  Google Scholar 

  59. Eng CM, Germain DP, Banikazemi M et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539–548

    Article  PubMed  Google Scholar 

  60. Hughes DA, Ramaswami U, Elliott P et al. Guidelines for the diagnosis and management of Anderson-Fabry Disease. Publications and statistics 2005. Available from http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4118404

  61. Connock M, Juarez-Garcia A, Frew E et al (2006) A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1. Health Technol Assess 10:iii–113

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lysosomal Storage Disorders Unit, Department of Academic Haematology, Royal Free Hospital and University College Medical School, London, UK

    D.A. Hughes

Authors
  1. D.A. Hughes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D.A. Hughes .

Editor information

Editors and Affiliations

  1. , Shaare Zedek Medical Center, Gaucher Clinic, Bayit Street 12, Jerusalem, 91034, Israel

    Deborah Elstein

  2. , Shaare Zedek Medical Center, Genetics Unit, Bayit Street 12, Jerusalem, 91031, Israel

    Gheona Altarescu

  3. University of Mainz, Children's Hospital, Langenbeckstrasse 1, Mainz, 55131, Germany

    Michael Beck

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Netherlands

About this chapter

Cite this chapter

Hughes, D. (2010). Fabry Disease in Females. In: Elstein, D., Altarescu, G., Beck, M. (eds) Fabry Disease. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9033-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-90-481-9033-1_21

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-9032-4

  • Online ISBN: 978-90-481-9033-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation